The following is a summary of “Perioperative Chemotherapy or Preoperative Chemoradiotherapy in Esophageal Cancer,” published ...

Adults with primary primary appendiceal adenocarcinoma face a higher risk of developing a second primary cancer, including ...

Merck MRK along with partner Eisai announced data from the phase III LEAP-015 study, which evaluated blockbuster PD-1 ...

The addition of lenvatinib and pembrolizumab to chemotherapy did not extend OS for certain patients with advanced ...

Merck and Eisai said on Friday a combination of their cancer therapies failed to extend the lives of patients with a type of ...

The following is a summary of “Biological characterization and clinical significance of cuproptosis-related genes in lung ...

The unsuccessful Phase III results are the latest to suggest that the blockbuster cancer drug is finally bumping up against ...

For patients with resectable esophageal adenocarcinoma, perioperative chemotherapy with fluorouracil, leucovorin, ox ...

Merck & Co. and Eisai have to deal with the reality that yet another phase 3 trial of their combination of Keytruda and ...

Certepetide plus chemotherapy showed signs of efficacy but failed to improve progression-free survival in metastatic PDAC in ...

Opdivo plus chemo showed long-term survival advantages in Chinese patients with advanced gastric, gastroesophageal junction ...